These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 28925954)

  • 1. Quantitative Structure-Activity Relationship Modeling of Kinase Selectivity Profiles.
    Kothiwale S; Borza C; Pozzi A; Meiler J
    Molecules; 2017 Sep; 22(9):. PubMed ID: 28925954
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Using the TOPS-MODE approach to fit multi-target QSAR models for tyrosine kinases inhibitors.
    Marzaro G; Chilin A; Guiotto A; Uriarte E; Brun P; Castagliuolo I; Tonus F; González-Díaz H
    Eur J Med Chem; 2011 Jun; 46(6):2185-92. PubMed ID: 21447431
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Computational proteomics of biomolecular interactions in the sequence and structure space of the tyrosine kinome: deciphering the molecular basis of the kinase inhibitors selectivity.
    Verkhivker GM
    Proteins; 2007 Mar; 66(4):912-29. PubMed ID: 17173284
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Visually interpretable models of kinase selectivity related features derived from field-based proteochemometrics.
    Subramanian V; Prusis P; Pietilä LO; Xhaard H; Wohlfahrt G
    J Chem Inf Model; 2013 Nov; 53(11):3021-30. PubMed ID: 24116714
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Structural biology contributions to tyrosine kinase drug discovery.
    Cowan-Jacob SW; Möbitz H; Fabbro D
    Curr Opin Cell Biol; 2009 Apr; 21(2):280-7. PubMed ID: 19208462
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Kinase selectivity potential for inhibitors targeting the ATP binding site: a network analysis.
    Huang D; Zhou T; Lafleur K; Nevado C; Caflisch A
    Bioinformatics; 2010 Jan; 26(2):198-204. PubMed ID: 19942586
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Kinase-kernel models: accurate in silico screening of 4 million compounds across the entire human kinome.
    Martin E; Mukherjee P
    J Chem Inf Model; 2012 Jan; 52(1):156-70. PubMed ID: 22133092
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A neural network-based QSAR approach for exploration of diverse multi-tyrosine kinase inhibitors and its comparison with a fragment- based approach.
    Ajmani S; Viswanadhan VN
    Curr Comput Aided Drug Des; 2013 Dec; 9(4):482-90. PubMed ID: 24138419
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Profile-QSAR: a novel meta-QSAR method that combines activities across the kinase family to accurately predict affinity, selectivity, and cellular activity.
    Martin E; Mukherjee P; Sullivan D; Jansen J
    J Chem Inf Model; 2011 Aug; 51(8):1942-56. PubMed ID: 21667971
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Abelson tyrosine-protein kinase 1 as principal target for drug discovery against leukemias. Role of the current computer-aided drug design methodologies.
    Speck-Planche A; Luan F; Cordeiro MN
    Curr Top Med Chem; 2012; 12(24):2745-62. PubMed ID: 23368101
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Structural insights into the ATP binding pocket of the anaplastic lymphoma kinase by site-directed mutagenesis, inhibitor binding analysis, and homology modeling.
    Gunby RH; Ahmed S; Sottocornola R; Gasser M; Redaelli S; Mologni L; Tartari CJ; Belloni V; Gambacorti-Passerini C; Scapozza L
    J Med Chem; 2006 Sep; 49(19):5759-68. PubMed ID: 16970400
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Anchor-based classification and type-C inhibitors for tyrosine kinases.
    Hsu KC; Sung TY; Lin CT; Chiu YY; Hsu JT; Hung HC; Sun CM; Barve I; Chen WL; Huang WC; Huang CT; Chen CH; Yang JM
    Sci Rep; 2015 Jun; 5():10938. PubMed ID: 26077136
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Identification of a New Inhibitor That Stabilizes Interleukin-2-Inducible T-Cell Kinase in Its Inactive Conformation.
    Hantani R; Hanawa S; Oie S; Umetani K; Sato T; Hantani Y
    SLAS Discov; 2019 Sep; 24(8):854-862. PubMed ID: 31247148
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Fragment-Based Discovery of a Small Molecule Inhibitor of Bruton's Tyrosine Kinase.
    Smith CR; Dougan DR; Komandla M; Kanouni T; Knight B; Lawson JD; Sabat M; Taylor ER; Vu P; Wyrick C
    J Med Chem; 2015 Jul; 58(14):5437-44. PubMed ID: 26087137
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cysteine mapping in conformationally distinct kinase nucleotide binding sites: application to the design of selective covalent inhibitors.
    Leproult E; Barluenga S; Moras D; Wurtz JM; Winssinger N
    J Med Chem; 2011 Mar; 54(5):1347-55. PubMed ID: 21322567
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Design and Analysis of the 4-Anilinoquin(az)oline Kinase Inhibition Profiles of GAK/SLK/STK10 Using Quantitative Structure-Activity Relationships.
    Asquith CRM; Laitinen T; Bennett JM; Wells CI; Elkins JM; Zuercher WJ; Tizzard GJ; Poso A
    ChemMedChem; 2020 Jan; 15(1):26-49. PubMed ID: 31675459
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Identification of type-II inhibitors using kinase structures.
    Lovering F; McDonald J; Whitlock GA; Glossop PA; Phillips C; Bent A; Sabnis Y; Ryan M; Fitz L; Lee J; Chang JS; Han S; Kurumbail R; Thorarensen A
    Chem Biol Drug Des; 2012 Nov; 80(5):657-64. PubMed ID: 22759374
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Exploiting the repertoire of CK2 inhibitors to target DYRK and PIM kinases.
    Cozza G; Sarno S; Ruzzene M; Girardi C; Orzeszko A; Kazimierczuk Z; Zagotto G; Bonaiuto E; Di Paolo ML; Pinna LA
    Biochim Biophys Acta; 2013 Jul; 1834(7):1402-9. PubMed ID: 23360763
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Exploring sequence-structure relationships in the tyrosine kinome space: functional classification of the binding specificity mechanisms for cancer therapeutics.
    Verkhivker GM
    Bioinformatics; 2007 Aug; 23(15):1919-26. PubMed ID: 17537753
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hit-to-lead studies on benzimidazole inhibitors of ITK: discovery of a novel class of kinase inhibitors.
    Snow RJ; Abeywardane A; Campbell S; Lord J; Kashem MA; Khine HH; King J; Kowalski JA; Pullen SS; Roma T; Roth GP; Sarko CR; Wilson NS; Winters MP; Wolak JP; Cywin CL
    Bioorg Med Chem Lett; 2007 Jul; 17(13):3660-5. PubMed ID: 17499505
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.